Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech company focused on obesity and metabolic health disorders, has announced its participation in multiple upcoming conferences in September 2025.
The company will present at three major investment conferences: the Cantor Global Healthcare Conference (Sept. 5), the H.C. Wainwright Global Investment Conference (Sept. 8), and the Morgan Stanley Global Healthcare Conference (Sept. 10). Additionally, Skye will participate in two medical conferences: Obesity Science & Innovation in Boston and the EASD Annual Meeting in Vienna, where they will present data on nimacimab, their CB1 receptor antibody for MAFLD treatment.
Skye Bioscience (Nasdaq: SKYE), biotech in fase clinica specializzata in obesità e disturbi metabolici, ha annunciato la propria partecipazione a diversi congressi previsti per settembre 2025.
L’azienda terrà presentazioni in tre importanti conferenze per investitori: il Cantor Global Healthcare Conference (5 set), l’H.C. Wainwright Global Investment Conference (8 set) e il Morgan Stanley Global Healthcare Conference (10 set). Inoltre, Skye sarà presente a due congressi medici: Obesity Science & Innovation a Boston e il EASD Annual Meeting a Vienna, dove presenterà dati su nimacimab, il suo anticorpo contro il recettore CB1 per il trattamento della MAFLD.
Skye Bioscience (Nasdaq: SKYE), una biotecnológica en fase clínica centrada en la obesidad y trastornos metabólicos, ha anunciado su asistencia a varias conferencias programadas para septiembre de 2025.
La compañía hará presentaciones en tres grandes conferencias de inversión: el Cantor Global Healthcare Conference (5 de sept.), el H.C. Wainwright Global Investment Conference (8 de sept.) y el Morgan Stanley Global Healthcare Conference (10 de sept.). Además, Skye participará en dos congresos médicos: Obesity Science & Innovation en Boston y la EASD Annual Meeting en Viena, donde expondrá datos sobre nimacimab, su anticuerpo contra el receptor CB1 para el tratamiento de la MAFLD.
Skye Bioscience (Nasdaq: SKYE)는 비만 및 대사 질환을 중심으로 하는 임상 단계 바이오텍으로, 2025년 9월에 예정된 다수의 학회 참여를 발표했습니다.
회사는 세 차례의 주요 투자자 컨퍼런스에서 발표할 예정입니다: Cantor Global Healthcare Conference(9월 5일), H.C. Wainwright Global Investment Conference(9월 8일), Morgan Stanley Global Healthcare Conference(9월 10일). 또한 Skye는 의료 학회인 Obesity Science & Innovation(보스턴)과 EASD Annual Meeting(비엔나)에 참여해 MAFLD 치료를 위한 CB1 수용체 표적 항체인 nimacimab의 데이터를 발표할 예정입니다.
Skye Bioscience (Nasdaq: SKYE), une biotech en stade clinique spécialisée dans l’obésité et les troubles métaboliques, a annoncé sa participation à plusieurs conférences prévues en septembre 2025.
La société présentera lors de trois grandes conférences pour investisseurs : le Cantor Global Healthcare Conference (5 sept.), le H.C. Wainwright Global Investment Conference (8 sept.) et le Morgan Stanley Global Healthcare Conference (10 sept.). Par ailleurs, Skye participera à deux congrès médicaux : Obesity Science & Innovation à Boston et le EASD Annual Meeting à Vienne, où elle dévoilera des données sur nimacimab, son anticorps dirigé contre le récepteur CB1 pour le traitement de la MAFLD.
Skye Bioscience (Nasdaq: SKYE), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Schwerpunkt auf Adipositas und Stoffwechselerkrankungen, hat seine Teilnahme an mehreren Konferenzen im September 2025 angekündigt.
Das Unternehmen wird auf drei großen Investorenkonferenzen präsentieren: der Cantor Global Healthcare Conference (5. Sept.), der H.C. Wainwright Global Investment Conference (8. Sept.) und der Morgan Stanley Global Healthcare Conference (10. Sept.). Zusätzlich wird Skye an zwei medizinischen Tagungen teilnehmen: Obesity Science & Innovation in Boston und dem EASD Annual Meeting in Wien, wo Daten zu nimacimab – ihrem CB1-Rezeptor-Antikörper zur Behandlung von MAFLD – vorgestellt werden.
- None.
- None.
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming investment and medical conferences:
Investment Conferences
- Cantor Global Healthcare Conference (New York)
Fireside Chat Sept. 5 8:00 am ET + 1x1 meetings
- H.C. Wainwright Global Investment Conference (New York)
Presentation Sept. 8 3:30 pm ET + 1x1 meetings
- Morgan Stanley Global Healthcare Conference (New York)
Fireside Chat Sept. 10 7:00 am ET + 1x1 meetings
Medical/Scientific Conferences
- Obesity Science & Innovation (Boston)
Keynote Panel Sept. 16 9:10 am ET
Title: Pipeline priorities - exploring leading and emerging targets shaping the future of obesity therapeutics
- European Association for the Study of Diabetes Annual Meeting (EASD) (Vienna, Austria)
Oral Presentation Sept. 19 10:15 am CET
Title: A multiple dose study to evaluate the safety and tolerability of nimacimab, a peripherally restricted, inhibitory CB1 receptor antibody in subjects with metabolic associated fatty liver disease (MAFLD)
Available webcasts will be accessible on Skye’s website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: (i) statements regarding the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, (ii) statements relating to any expectations regarding the efficacy and therapeutic potential of nimacimab as a monotherapy or in combination with a GLP-1 targeted drug, including expectations based on preclinical DIO models, (iii) statements regarding nimacimab’s potential to change weight loss standards of care, (iv) statements regarding superior potency of nimacimab to other small molecule CB1 inhibitors based on nimacimab’s mechanism of action and (v) statements regarding the timing of receipt of final data from Skye’s Phase 2 obesity study of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
When is Skye Bioscience (SKYE) presenting at the Cantor Global Healthcare Conference 2025?
What will Skye Bioscience present at the EASD Annual Meeting 2025?
How many conferences will Skye Bioscience (SKYE) attend in September 2025?
Where can investors access Skye Bioscience's conference presentations?
